FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024645505> ?p ?o ?g. }

• W3024645505 endingPage "118" @default.
• W3024645505 startingPage "113" @default.
• W3024645505 abstract "Background: The goal of this study was to evaluate the anticancer and testosteroneinhibitory effects of 2‘-[(E) androst-5-en-17-ylidene]methyl-4‘,5‘-dihydro-1‘,3‘-oxazole-3β-oleate (Alsevirone-NF). Materials and Methods: PC-3, DU-145, LnCap and 22rv1 prostate cancer cell lines were used for MTT assay. 22rv1 subcutaneous cancer xenografts in Balb/c nude mice were used for in vivo efficacy experiments. Testosterone level was determined after repeated administration of Abiraterone 20, 100 or 200 mg/kg vs Alsevirone-NF 5, 25 or 50 mg/kg daily for 14 days. Results: Alsevirone-NF induced more significant cytotoxicity against PC3, 22rv1 and DU-145 cell lines compared to Abiraterone or Alsevirone-treated control: IC50 7.1 vs 20.6 vs 29.1 μg/ml, 7.7 vs 20.0 vs 12.7 μg/ml, 3.8 vs 43.4 vs 8.5 μg/ml, respectively. IC50 in LnCap cells was almost equal for all three studied agents, 29.2 vs 26.2 vs 30.2 μg/ml for Abiraterone, Alsevirone and Alsevirone-NF. In gonadectomized mice, significant reduction of testosterone level was observed in mice receiving Alsevirone-NF in a maximum single dose of 50 mg/kg (cumulative dose 700 mg/kg): 0.2 nmol/l vs 0.57 nmol/l in control group and 0.83 nmol/l in Abiraterone group, single dose 100 mg/kg. Statistically significant anticancer effect in vivo was obtained on day 11 after the start of treatment: Abiraterone T/C = 27% (p<0.05), Alsevirone-NF single dose 1200 mg/kg Т/С = 45% (p<0.05). Conclusion: Alsevirone-NF exhibited higher cytotoxic activity, comparable anticancer effect in 22rv1-bearing Balb/c nude mice and provided a more significant reduction of testosterone level in gonadectomized mice in direct comparison against Abiraterone." @default.
• W3024645505 created "2020-05-21" @default.
• W3024645505 creator A5008803268 @default.
• W3024645505 creator A5016025831 @default.
• W3024645505 creator A5035656871 @default.
• W3024645505 creator A5039138433 @default.
• W3024645505 creator A5042745987 @default.
• W3024645505 creator A5048857257 @default.
• W3024645505 creator A5056913849 @default.
• W3024645505 creator A5065217106 @default.
• W3024645505 creator A5073687302 @default.
• W3024645505 creator A5076047738 @default.
• W3024645505 creator A5076374408 @default.
• W3024645505 date "2020-11-06" @default.
• W3024645505 modified "2023-10-01" @default.
• W3024645505 title "Alsevirone-NF Reduces Serum Testosterone and Inhibits Prostate Cancer Xenograft Growth in Balb/c Nude Mice" @default.
• W3024645505 cites W1585705786 @default.
• W3024645505 cites W2034670389 @default.
• W3024645505 cites W2061510929 @default.
• W3024645505 cites W2077781847 @default.
• W3024645505 cites W2081201545 @default.
• W3024645505 cites W2133489902 @default.
• W3024645505 cites W2148047944 @default.
• W3024645505 cites W2170544517 @default.
• W3024645505 cites W2278392405 @default.
• W3024645505 cites W2472772837 @default.
• W3024645505 cites W2511849203 @default.
• W3024645505 cites W2516152350 @default.
• W3024645505 cites W2607068605 @default.
• W3024645505 cites W2742217960 @default.
• W3024645505 cites W2755428328 @default.
• W3024645505 cites W2768246551 @default.
• W3024645505 cites W2968436284 @default.
• W3024645505 cites W2982291463 @default.
• W3024645505 cites W2992800977 @default.
• W3024645505 doi "https://doi.org/10.2174/2212697x07999200511082225" @default.
• W3024645505 hasPublicationYear "2020" @default.
• W3024645505 type Work @default.
• W3024645505 sameAs 3024645505 @default.
• W3024645505 citedByCount "1" @default.
• W3024645505 countsByYear W30246455052023 @default.
• W3024645505 crossrefType "journal-article" @default.
• W3024645505 hasAuthorship W3024645505A5008803268 @default.
• W3024645505 hasAuthorship W3024645505A5016025831 @default.
• W3024645505 hasAuthorship W3024645505A5035656871 @default.
• W3024645505 hasAuthorship W3024645505A5039138433 @default.
• W3024645505 hasAuthorship W3024645505A5042745987 @default.
• W3024645505 hasAuthorship W3024645505A5048857257 @default.
• W3024645505 hasAuthorship W3024645505A5056913849 @default.
• W3024645505 hasAuthorship W3024645505A5065217106 @default.
• W3024645505 hasAuthorship W3024645505A5073687302 @default.
• W3024645505 hasAuthorship W3024645505A5076047738 @default.
• W3024645505 hasAuthorship W3024645505A5076374408 @default.
• W3024645505 hasConcept C121608353 @default.
• W3024645505 hasConcept C126322002 @default.
• W3024645505 hasConcept C134018914 @default.
• W3024645505 hasConcept C150903083 @default.
• W3024645505 hasConcept C185592680 @default.
• W3024645505 hasConcept C190283241 @default.
• W3024645505 hasConcept C202751555 @default.
• W3024645505 hasConcept C207001950 @default.
• W3024645505 hasConcept C2777752497 @default.
• W3024645505 hasConcept C2779279991 @default.
• W3024645505 hasConcept C2779723316 @default.
• W3024645505 hasConcept C2780192828 @default.
• W3024645505 hasConcept C2780783641 @default.
• W3024645505 hasConcept C2780940892 @default.
• W3024645505 hasConcept C55493867 @default.
• W3024645505 hasConcept C71924100 @default.
• W3024645505 hasConcept C86803240 @default.
• W3024645505 hasConcept C98274493 @default.
• W3024645505 hasConceptScore W3024645505C121608353 @default.
• W3024645505 hasConceptScore W3024645505C126322002 @default.
• W3024645505 hasConceptScore W3024645505C134018914 @default.
• W3024645505 hasConceptScore W3024645505C150903083 @default.
• W3024645505 hasConceptScore W3024645505C185592680 @default.
• W3024645505 hasConceptScore W3024645505C190283241 @default.
• W3024645505 hasConceptScore W3024645505C202751555 @default.
• W3024645505 hasConceptScore W3024645505C207001950 @default.
• W3024645505 hasConceptScore W3024645505C2777752497 @default.
• W3024645505 hasConceptScore W3024645505C2779279991 @default.
• W3024645505 hasConceptScore W3024645505C2779723316 @default.
• W3024645505 hasConceptScore W3024645505C2780192828 @default.
• W3024645505 hasConceptScore W3024645505C2780783641 @default.
• W3024645505 hasConceptScore W3024645505C2780940892 @default.
• W3024645505 hasConceptScore W3024645505C55493867 @default.
• W3024645505 hasConceptScore W3024645505C71924100 @default.
• W3024645505 hasConceptScore W3024645505C86803240 @default.
• W3024645505 hasConceptScore W3024645505C98274493 @default.
• W3024645505 hasIssue "2" @default.
• W3024645505 hasLocation W30246455051 @default.
• W3024645505 hasOpenAccess W3024645505 @default.
• W3024645505 hasPrimaryLocation W30246455051 @default.
• W3024645505 hasRelatedWork W1988486434 @default.
• W3024645505 hasRelatedWork W1998113603 @default.
• W3024645505 hasRelatedWork W1999611386 @default.
• W3024645505 hasRelatedWork W1999831221 @default.
• W3024645505 hasRelatedWork W2027237635 @default.

• next